Skip to content

AERIAL Trial: Antiplatelet Therapy in Heart Transplantation

Heart Transplant | Cardiac Allograft Vasculopathy

Cardiac allograft vasculopathy is a common complication affecting heart transplant patients. This condition causes narrowing of the heart arteries leading to graft dysfunction. The research team is investigating whether early antiplatelet therapy post heart transplant can prevent the development of CAV. This study will determine the feasibility of a large multicenter randomized placebo-controlled trial to answer this question.

null

Participation Requirements

  • Sex:

    ALL

  • Eligible Ages:

    18 and up

Participation Criteria

Inclusion Criteria:

1. Heart transplant
2. Age ≥18 years
3. Able to provide informed consent

Exclusion Criteria:

1. Allergy or known intolerance to aspirin
2. Allergy or known intolerance to clopidogrel
3. Intracranial hemorrhage ≤14 days
4. Bleeding disorder
5. Platelet count \<50 x 109/L
6. History of aspirin related gastrointestinal bleeding or ulcers
7. Non-cardiac indication for antiplatelet therapy
8. Anticoagulation \>3 months
9. Allergy to iodinated contrast
10. Unable to undergo coronary angiography due to glomerular filtration rate ≤30 mL/min/1.73 m2 for non-dialysis patients
11. Unable to undergo coronary angiography due to unsuitable vascular access
12. Combined solid organ transplantation.

Study Location

Toronto General Hospital UHN
Toronto General Hospital UHN
Toronto, Ontario
Canada

Contact Study Team

Primary Contact

Heather Ross

University of Ottawa Heart Institute
University of Ottawa Heart Institute
Ottawa, Ontario
Canada

Contact Study Team

Primary Contact

Sharon Chih

St.Pauls Hospital
St.Pauls Hospital
Vancouver, British Columbia
Canada

Contact Study Team

Primary Contact

Mustafa Toma

Study Sponsored By
Ottawa Heart Institute Research Corporation
Participants Required
More Information
Study ID: NCT04770012